Compare Abeona Therapeutics Inc (ABEO) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs NetEase Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while NetEase Inc trades at $134.15 (market cap $83.83B). The key difference: NetEase Inc is far larger — about 224.6× Abeona Therapeutics Inc's market cap, and NetEase Inc pays a 2.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NTES | |
|---|---|---|
Market Cap | $373.32M | $83.83B |
Sector | Health | Media |
52-Week High | $7.23 | $159.34 |
52-Week Low | $4.17 | $109.26 |
Enterprise Value | $228.22M | $60.31B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NetEase (NTES) trades at $130.82, up 2.81% today, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings that beat estimates, with revenue growth to $112.63B in 2025 and a net income margin of 29.84%. Recent news highlights international expansion and a $0.72 dividend payment scheduled for June 2026.
The stock presents a compelling value with a P/E of 16.83 and robust profitability metrics. Analyst consensus is strongly bullish with 82% buy ratings and a 34.7% upside potential. Key risks include reliance on the Chinese market and competitive pressures in gaming. Cash flow trends show volatility, but the balance sheet remains strong with $137.58B in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
